The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but betting in companies heavily reliant on generic versions presents a challenging picture. While early earnings were significant, the expiration of patents and the rise of less expensive alternatives have weakened market share. Thus, a thorough assessment of ongoing